Literature DB >> 29802470

Primary adrenal diffuse large B cell lymphoma: a clinicopathological and molecular study from China.

Jing Zhang1, Jian Sun1, Jun Feng2, Yufeng Luo1, Qing Ling1, Shafei Wu1, Xuan Zeng1, Zhiyong Liang3.   

Abstract

Primary adrenal lymphoma is a rare entity that, in most cases, is derived from B cells. The most commonly seen primary adrenal lymphoma is diffuse large B cell lymphoma (DLBCL). To better understand the clinicopathological and molecular features of these tumors, we studied 14 Chinese patients with DLBCL who initially presented with an adrenal tumor. The clinicopathological features of the 14 primary adrenal DLBCL cases were retrospectively reviewed using immunohistochemistry, immunoglobulin gene rearrangement analysis, evaluation of Epstein-Barr virus status, and fluorescence in situ hybridization. Patient age ranged from 43 to 69 years, with a mean age of 58 years. The patients most commonly presented with abdominal pain and adrenal mass. Ten patients exhibited bilateral adrenal masses, and four had unilateral adrenal masses (three left, one right). Thirteen of 14 DLBCLs were DLBCL not otherwise specified, and one was an intravascular large B cell lymphoma. According to the algorithm of Hans et al. (Blood 103:275-282, 2004), 13 and 1 cases were classified as the non-germinal center B-cell-like subtype and the germinal center B-cell-like subtype, respectively. The Ki-67 index ranged from 35 to 80%. Epstein-Barr virus-encoded RNA was detected by in situ hybridization in 6 of the 12 available cases. Two patients showed BCL-6 rearrangements. The follow-up period ranged from 1 to 87 months. During the follow-up period, four patients died of the disease, five were alive with the disease, four were alive without disease, and one was lost during the follow-up period. In summary, most primary adrenal lymphomas are non-germinal-center B-cell-like subtype DLBCLs, which have high proliferative activity and a poor prognosis.

Entities:  

Keywords:  Adrenal lymphoma; Clinicopathological; Diffuse large B cell lymphoma; Fluorescence in situ hybridization

Mesh:

Substances:

Year:  2018        PMID: 29802470     DOI: 10.1007/s00428-018-2378-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  38 in total

1.  Transient spontaneous regression of aggressive non-Hodgkin's lymphoma confined to the adrenal glands.

Authors:  T Fujiwara; M Kawamura; A Sasaki; H Asahi; S Sasou; S Itoh; K Hiramori
Journal:  Ann Hematol       Date:  2001-09       Impact factor: 3.673

2.  De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.

Authors:  Motoko Yamaguchi; Masao Seto; Masataka Okamoto; Ryo Ichinohasama; Naoya Nakamura; Tadashi Yoshino; Junji Suzumiya; Takuhei Murase; Ikuo Miura; Takashi Akasaka; Jun-ichi Tamaru; Ritsuro Suzuki; Yoshitoyo Kagami; Masami Hirano; Yasuo Morishima; Ryuzo Ueda; Hiroshi Shiku; Shigeo Nakamura
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

3.  Non-germinal cell phenotype and bcl-2 expression in primary adrenal diffuse large B-cell lymphoma.

Authors:  Masaru Ide; Noriyasu Fukushima; Takashi Hisatomi; Naoko Tsuneyoshi; Mariko Tanaka; Masako Yokoo; Rika Tomimasu; Noriko Funai; Eisaburo Sueoka
Journal:  Leuk Lymphoma       Date:  2007-11

4.  A case of intravascular large B-cell lymphoma in the left adrenal and another tumor in the right adrenal detected by (18)F-FDG PET/CT.

Authors:  Wen Li; Wei Lin; Chao Ma; Lingyu Zhang; Hongjun Sun
Journal:  Hell J Nucl Med       Date:  2016-03-01       Impact factor: 1.102

5.  Intravascular lymphoma: an unusual diagnostic outcome of an incidentally detected adrenal mass.

Authors:  Sumathi Srivatsa; Jyotirmay Sharma; Sanjay Logani
Journal:  Endocr Pract       Date:  2008-10       Impact factor: 3.443

6.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

7.  Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age.

Authors:  Ting-Xun Lu; Jin-Hua Liang; Yi Miao; Lei Fan; Li Wang; Xiao-Yan Qu; Lei Cao; Qi-Xing Gong; Zhen Wang; Zhi-Hong Zhang; Wei Xu; Jian-Yong Li
Journal:  Sci Rep       Date:  2015-07-23       Impact factor: 4.379

8.  Acute adrenal insufficiency secondary to bilateral adrenal B-cell lymphoma: a case report and review of the literature.

Authors:  Carlos De Miguel Sánchez; Luis Ruiz; Jose Luis González; Jose Luis Hernández
Journal:  Ecancermedicalscience       Date:  2016-04-18

9.  Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL).

Authors:  Yu Ri Kim; Jin Seok Kim; Yoo Hong Min; Dok Hyunyoon; Ho-Jin Shin; Yeung-Chul Mun; Yong Park; Young Rok Do; Seong Hyun Jeong; Joon Seong Park; Sung Yong Oh; Suee Lee; Eun Kyung Park; Joung-Soon Jang; Won-Sik Lee; Hwe-Won Lee; Hyeonseok Eom; Jae-Sook Ahn; Jae-Heon Jeong; Sun Kyung Baek; Seok Jin Kim; Won Seog Kim; Cheolwon Suh
Journal:  J Hematol Oncol       Date:  2012-08-13       Impact factor: 17.388

10.  Bilateral adrenal masses: a single-centre experience.

Authors:  Nilesh Lomte; Tushar Bandgar; Shruti Khare; Swati Jadhav; Anurag Lila; Manjunath Goroshi; Rajeev Kasaliwal; Kranti Khadilkar; Nalini S Shah
Journal:  Endocr Connect       Date:  2016-04-01       Impact factor: 3.335

View more
  1 in total

1.  A Novel Diagnostic Model for Primary Adrenal Lymphoma.

Authors:  Kai Yu; Qingping Xue; Fangli Zhou; Haoming Tian; Qiao Xiang; Tao Chen; Yan Ren
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-02       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.